Eliana Clark - Jul 1, 2022 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
EVP, Chief Technical Officer
Signature
James Basta, attorney-in-fact
Stock symbol
NTLA
Transactions as of
Jul 1, 2022
Transactions value $
-$76,357
Form type
4
Date filed
1/6/2023, 04:21 PM
Previous filing
Mar 7, 2022
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Sale -$5.43K -105 -0.65% $51.74 16.2K Jul 1, 2022 Direct F1
transaction NTLA Common Stock Sale -$7.96K -231 -1.41% $34.48 16.2K Jan 3, 2023 Direct F2
transaction NTLA Common Stock Sale -$63K -1.69K -10.47% $37.21 14.5K Jan 4, 2023 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of 105 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2022.
F2 Sale of 231 shares that were acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on December 31, 2022.
F3 Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.